Latest Methylgene Inc (MYLGF) Headlines
10-Q: STARRETT L S CO
Edgar Online - Thu Jan 30, 1:40PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12-15
UK Minister for Africa Calls for an End to Hostilities in South Sudan [press release]
All Africa Global Media - Fri Dec 20, 12:31PM CST
Mr Mark Bensberg has been appointed Her Majesty's Ambassador to Cote d'Ivoire.
USAID's Gast On Situation in Central African Republic [document]
All Africa Global Media - Fri Dec 20, 12:31PM CST
Testimony by Assistant Administrator Earl Gast Before the Senate Subcommittee on Africa: Responding to the Humanitarian, Security, and Governance Crisis in the Central African Republic
Hodgkin Lymphoma - Pipeline Review, H2 2013 Out Now for Review
M2 - Tue Aug 06, 11:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gzwnhz/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Hodgkin Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma. Hodgkin Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Hodgkin Lymphoma. - A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Bristol-Myers Squibb Company - Seattle Genetics, Inc. - Gamida Cell Ltd. - Plexxikon Inc. - Novartis AG - Cell Therapeutics, Inc. - 4SC AG - Hana Biosciences, Inc. - MethylGene Inc - Cytokinetics, Inc - Spectrum Pharmaceuticals, Inc. - Affimed Therapeutics AG - Actinium Pharmaceuticals, Inc. - Philogen S.p.A. - Italfarmaco S.p.A. - MAT Biopharma - Stemline Therapeutics, Inc. - Syndax Pharmaceuticals, Inc. - Xencor, Inc. - TaiGen Biotechnology Co., Ltd. - Johnson & Johnson Pharmaceutical Research & Development, L.L.C. - Sigma-Tau Pharmaceuticals, Inc. - Coridon Pty Ltd For more information visit http://www.researchandmarkets.com/research/gz...n_lymphoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mirati Therapeutics to Commence Trading on the NASDAQ
Marketwire - Mon Jul 15, 7:15AM CDT
Mirati Therapeutics Inc. ("Mirati Therapeutics" or the "Company") (TSX: MYG) (NASDAQ: MRTX) today announced that the NASDAQ Capital Market ("NASDAQ") has informed the Company that its common stock will commence trading on the NASDAQ beginning today, July 15, 2013 under the ticker symbol MRTX.
Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement
Marketwire - Fri Jun 28, 7:16AM CDT
MethylGene Inc. ("MethylGene") (TSX: MYG) and Mirati Therapeutics Inc. ("Mirati Therapeutics") today announced the successful completion, effective June 28, 2013, of the previously announced plan of arrangement (the "Arrangement"), whereby, among other things, MethylGene would migrate to the State of Delaware in the United States of America. Under the Arrangement, Mirati Therapeutics, a holding company, has become the ultimate parent corporation of MethylGene and its subsidiaries. Each MethylGene shareholder received one share of Mirati Therapeutics common stock ("Mirati Share") for every 50 common shares of MethylGene held, having the effect of a 1 for 50 reverse split. In addition, all outstanding warrants and options have become exerciseable for Mirati Shares and the exercise price and the number of common shares issuable thereunder have been proportionately adjusted to reflect the 1 for 50 effective reverse split. The Mirati Shares are expected to commence trading on the TSX on July 3, 2013, under the s
MethylGene Shareholders Approve the Plan of Arrangement to Reincorporate in the United States as Mirati Therapeutics Inc.
Marketwire - Tue Jun 25, 11:03AM CDT
MethylGene Inc. ("MethylGene") (TSX: MYG) today announced that at its Annual and Special Meeting of Shareholders held in Montreal, Quebec (the "Meeting"), that over 99.99% of the votes cast by shareholders approved the previously announced plan of arrangement (the "Arrangement"), whereby, among other things, the company would migrate to the State of Delaware in the United States of America. Under the Arrangement, Mirati Therapeutics Inc. ("Mirati"), the holding company and wholly-owned subsidiary, will become the ultimate parent corporation of MethylGene and its subsidiaries, by acquiring all of the issued and outstanding common shares of MethylGene in exchange for 1 Mirati share for every 50 common shares of MethylGene.
MethylGene Presents Clinical Data on Mocetinostat at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwire - Mon Jun 03, 7:02AM CDT
MethylGene Inc. (TSX: MYG) today announced that clinical data for mocetinostat, the spectrum selective histone deacetylase (HDAC) inhibitor, was presented at the 2013 ASCO Annual Meeting in Chicago, Illinois.
MethylGene to Present at the Jefferies 2013 Healthcare Conference
Marketwire - Thu May 30, 7:02AM CDT
MethylGene Inc. (TSX: MYG) today announced that Charles Baum, MD, PhD, President and Chief Executive Officer, will present an overview of the Company at the Jefferies 2013 Healthcare Conference which will be held in New York City, June 3-6 2013. The Jefferies Healthcare Conference is one of the largest gatherings of institutional investors, private equity investors, venture capitalists and healthcare industry executives.
MethylGene to Present Mocetinostat Data at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwire - Tue May 28, 7:02AM CDT
MethylGene Inc. (TSX: MYG) today announced that clinical data for mocetinostat, the spectrum selective histone deacetylase (HDAC) inhibitor, will be presented at the 2013 ASCO Annual Meeting to be held in Chicago, Illinois from May 31st to June 4, 2013.
MethylGene Reports First Quarter 2013 Financial Results
Marketwire - Mon May 13, 7:25AM CDT
MethylGene Inc. ("MethylGene" or the "Company") (TSX: MYG) today reported financial results for the first quarter ended March 31, 2013.
MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ
Marketwire - Thu May 09, 7:31AM CDT
MethylGene Inc. ("MethylGene") (TSX: MYG) today announced that its Board of Directors (the "Board"), after careful analysis, consideration and advice from its legal, tax and accounting advisors, has unanimously approved a proposal to change MethylGene's jurisdiction of incorporation from the federal jurisdiction of Canada to the State of Delaware in the United States of America by way of a court-approved plan of arrangement (the "Arrangement").
Follicular Lymphoma - Pipeline Review, H1 2013 Available Now for Analysis
M2 - Thu Apr 11, 12:51PM CDT
Research and Markets has announced the addition of the "Follicular Lymphoma - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Follicular Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Follicular Lymphoma. Follicular Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Follicular Lymphoma. - A review of the Follicular Lymphoma pro
MethylGene Presents Preclinical Data on MG516 at the American Association for Cancer Research Annual Meeting
Marketwire - Mon Apr 08, 7:03AM CDT
MethylGene Inc. (TSX: MYG) today announced that preclinical data for the kinase inhibitor MG516 was presented at the American Association for Cancer Research (AACR) Annual Meeting held in Washington DC. In a poster entitled "Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies" data was presented showing that MG516 possesses potent inhibitory activity against a spectrum of tyrosine kinase receptor targets including Eph receptors and Ret as well as Met, Axl and VEGF-R family members. The study incorporated data from in vitro kinase and cell-based analyses. In a broad variety of animal models of human cancer, MG516 demonstrated significant inhibition of tumor growth accompanied by suppression of the target kinases. MG516 also reversed resistance to the VEGFR inhibitor sunitinib in an in vivo preclinical tumor model.
10-Q: STARRETT L S CO
Edgar Online - Thu Jan 30, 1:40PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12-15
UK Minister for Africa Calls for an End to Hostilities in South Sudan [press release]
All Africa Global Media - Fri Dec 20, 12:31PM CST
Mr Mark Bensberg has been appointed Her Majesty's Ambassador to Cote d'Ivoire.
USAID's Gast On Situation in Central African Republic [document]
All Africa Global Media - Fri Dec 20, 12:31PM CST
Testimony by Assistant Administrator Earl Gast Before the Senate Subcommittee on Africa: Responding to the Humanitarian, Security, and Governance Crisis in the Central African Republic
Hodgkin Lymphoma - Pipeline Review, H2 2013 Out Now for Review
M2 - Tue Aug 06, 11:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gzwnhz/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Hodgkin Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma. Hodgkin Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Hodgkin Lymphoma. - A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Bristol-Myers Squibb Company - Seattle Genetics, Inc. - Gamida Cell Ltd. - Plexxikon Inc. - Novartis AG - Cell Therapeutics, Inc. - 4SC AG - Hana Biosciences, Inc. - MethylGene Inc - Cytokinetics, Inc - Spectrum Pharmaceuticals, Inc. - Affimed Therapeutics AG - Actinium Pharmaceuticals, Inc. - Philogen S.p.A. - Italfarmaco S.p.A. - MAT Biopharma - Stemline Therapeutics, Inc. - Syndax Pharmaceuticals, Inc. - Xencor, Inc. - TaiGen Biotechnology Co., Ltd. - Johnson & Johnson Pharmaceutical Research & Development, L.L.C. - Sigma-Tau Pharmaceuticals, Inc. - Coridon Pty Ltd For more information visit http://www.researchandmarkets.com/research/gz...n_lymphoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mirati Therapeutics to Commence Trading on the NASDAQ
Marketwire - Mon Jul 15, 7:15AM CDT
Mirati Therapeutics Inc. ("Mirati Therapeutics" or the "Company") (TSX: MYG) (NASDAQ: MRTX) today announced that the NASDAQ Capital Market ("NASDAQ") has informed the Company that its common stock will commence trading on the NASDAQ beginning today, July 15, 2013 under the ticker symbol MRTX.
Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement
Marketwire - Fri Jun 28, 7:16AM CDT
MethylGene Inc. ("MethylGene") (TSX: MYG) and Mirati Therapeutics Inc. ("Mirati Therapeutics") today announced the successful completion, effective June 28, 2013, of the previously announced plan of arrangement (the "Arrangement"), whereby, among other things, MethylGene would migrate to the State of Delaware in the United States of America. Under the Arrangement, Mirati Therapeutics, a holding company, has become the ultimate parent corporation of MethylGene and its subsidiaries. Each MethylGene shareholder received one share of Mirati Therapeutics common stock ("Mirati Share") for every 50 common shares of MethylGene held, having the effect of a 1 for 50 reverse split. In addition, all outstanding warrants and options have become exerciseable for Mirati Shares and the exercise price and the number of common shares issuable thereunder have been proportionately adjusted to reflect the 1 for 50 effective reverse split. The Mirati Shares are expected to commence trading on the TSX on July 3, 2013, under the s
MethylGene Shareholders Approve the Plan of Arrangement to Reincorporate in the United States as Mirati Therapeutics Inc.
Marketwire - Tue Jun 25, 11:03AM CDT
MethylGene Inc. ("MethylGene") (TSX: MYG) today announced that at its Annual and Special Meeting of Shareholders held in Montreal, Quebec (the "Meeting"), that over 99.99% of the votes cast by shareholders approved the previously announced plan of arrangement (the "Arrangement"), whereby, among other things, the company would migrate to the State of Delaware in the United States of America. Under the Arrangement, Mirati Therapeutics Inc. ("Mirati"), the holding company and wholly-owned subsidiary, will become the ultimate parent corporation of MethylGene and its subsidiaries, by acquiring all of the issued and outstanding common shares of MethylGene in exchange for 1 Mirati share for every 50 common shares of MethylGene.
MethylGene Presents Clinical Data on Mocetinostat at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwire - Mon Jun 03, 7:02AM CDT
MethylGene Inc. (TSX: MYG) today announced that clinical data for mocetinostat, the spectrum selective histone deacetylase (HDAC) inhibitor, was presented at the 2013 ASCO Annual Meeting in Chicago, Illinois.
MethylGene to Present at the Jefferies 2013 Healthcare Conference
Marketwire - Thu May 30, 7:02AM CDT
MethylGene Inc. (TSX: MYG) today announced that Charles Baum, MD, PhD, President and Chief Executive Officer, will present an overview of the Company at the Jefferies 2013 Healthcare Conference which will be held in New York City, June 3-6 2013. The Jefferies Healthcare Conference is one of the largest gatherings of institutional investors, private equity investors, venture capitalists and healthcare industry executives.
MethylGene to Present Mocetinostat Data at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwire - Tue May 28, 7:02AM CDT
MethylGene Inc. (TSX: MYG) today announced that clinical data for mocetinostat, the spectrum selective histone deacetylase (HDAC) inhibitor, will be presented at the 2013 ASCO Annual Meeting to be held in Chicago, Illinois from May 31st to June 4, 2013.
MethylGene Reports First Quarter 2013 Financial Results
Marketwire - Mon May 13, 7:25AM CDT
MethylGene Inc. ("MethylGene" or the "Company") (TSX: MYG) today reported financial results for the first quarter ended March 31, 2013.
MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ
Marketwire - Thu May 09, 7:31AM CDT
MethylGene Inc. ("MethylGene") (TSX: MYG) today announced that its Board of Directors (the "Board"), after careful analysis, consideration and advice from its legal, tax and accounting advisors, has unanimously approved a proposal to change MethylGene's jurisdiction of incorporation from the federal jurisdiction of Canada to the State of Delaware in the United States of America by way of a court-approved plan of arrangement (the "Arrangement").
Follicular Lymphoma - Pipeline Review, H1 2013 Available Now for Analysis
M2 - Thu Apr 11, 12:51PM CDT
Research and Markets has announced the addition of the "Follicular Lymphoma - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Follicular Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Follicular Lymphoma. Follicular Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Follicular Lymphoma. - A review of the Follicular Lymphoma pro
MethylGene Presents Preclinical Data on MG516 at the American Association for Cancer Research Annual Meeting
Marketwire - Mon Apr 08, 7:03AM CDT
MethylGene Inc. (TSX: MYG) today announced that preclinical data for the kinase inhibitor MG516 was presented at the American Association for Cancer Research (AACR) Annual Meeting held in Washington DC. In a poster entitled "Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies" data was presented showing that MG516 possesses potent inhibitory activity against a spectrum of tyrosine kinase receptor targets including Eph receptors and Ret as well as Met, Axl and VEGF-R family members. The study incorporated data from in vitro kinase and cell-based analyses. In a broad variety of animal models of human cancer, MG516 demonstrated significant inhibition of tumor growth accompanied by suppression of the target kinases. MG516 also reversed resistance to the VEGFR inhibitor sunitinib in an in vivo preclinical tumor model.
